Dr. Godwin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-520-5700
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2015 - 2018- University of WashingtonResidency, Internal Medicine, 2012 - 2015
Washington University in St. Louis School of MedicineClass of 2012
Certifications & Licensure
WA State Medical License 2014 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 28 citationsAccuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neop...Raffaele Palmieri, Megan Othus, Anna B. Halpern, Mary-Elizabeth M. Percival, Colin D. Godwin
Journal of Clinical Oncology. 2020-10-08 - 165 citationsGemtuzumab ozogamicin in acute myeloid leukemiaColin D. Godwin, Robert Peter Gale, Roland B. Walter
Leukemia. 2017-06-13 - 171 citationsComparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hemato...Roland B. Walter, Boglarka Gyurkocza, Barry E. Storer, Colin D. Godwin, John M. Pagel
Leukemia. 2015-01-01
Journal Articles
- Relationship Between CD33 Expression, Splicing Polymorphism, and in Vitro Cytotoxicity of Gemtuzumab Ozogamicin and the CD33/CD3 BiTErAMG 330Colin D Godwin, Roland B Walter, Haematologica
Abstracts/Posters
- Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)Colin D. Godwin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myel...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Northwestern Mutual Funds $600,000 in New Grants for Childhood Cancer ResearchOctober 15th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
